Regeneron Pharmaceuticals News

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

30.09.21	Regeneron's REGEN-COV Data Show Supportive Results In Patients Hospitalized With COVID-19 (RTTNews)
30.09.21	New REGEN-COV™ (casirivimab and imdevimab) Data Show Supportive Results in Patients Hospitalized with COVID-19 (PR Newswire)
29.09.21	New England Journal of Medicine Publishes Positive Phase 3 Trial Results for REGEN-COV™ (casirivimab and imdevimab) to Treat COVID-19 (PR Newswire)
28.09.21	Regeneron's Supplemental BLA For Libtayo To Treat Cervical Cancer Gets Priority Review (RTTNews)
28.09.21	FDA Accepts Libtayo® (cemiplimab-rwlc) for Priority Review for Advanced Cervical Cancer (PR Newswire)
21.09.21	New Dupixent® (dupilumab) Data in Patients as Young as Six Years Old With Moderate-to-Severe Atopic Dermatitis to Be Presented at WCPD and EADV (PR Newswire)
19.09.21	ESMO Late-breaking Data Show Libtayo® (cemiplimab) and Chemotherapy First-line Treatment Combination Significantly Improved Overall Survival in Patients with Advanced NSCLC (PR Newswire)
15.09.21	Regeneron To Supply Additional 1.4 Mln Doses Of COVID-19 Therapy To U.S. (RTTNews)
14.09.21	Regeneron Announces New U.S. Government Agreement to Purchase Additional Doses of REGEN-COV™ (casirivimab and imdevimab) Antibody Cocktail (PR Newswire)
08.09.21	Regeneron Announces Investor Conference Presentations (PR Newswire)
30.08.21	Regeneron : Phase 3 Trial Of Dupixent On Atopic Dermatitis Meets Primary And Secondary Endpoints (RTTNews)
30.08.21	Dupixent® (dupilumab) Pivotal Trial Meets All Primary and Secondary Endpoints Becoming First Biologic Medicine to Significantly Reduce Signs and Symptoms of Moderate-to-severe Atopic Dermatitis in... (PR Newswire)
24.08.21	Regeneron Announces Encouraging Topline Phase 2 Data of High-dose aflibercept in Wet Age-related Macular Degeneration (PR Newswire)
20.08.21	U.K. Authorizes Regeneron's Antibody Cocktail To Prevent & Treat Acute COVID-19 Infection (RTTNews)
20.08.21	UK Authorizes Regeneron Antibody Cocktail to Prevent and Treat Acute COVID-19 Infection (PR Newswire)
05.08.21	Daimler Truck, Cummins Partner For Medium-duty Engines (RTTNews)
05.08.21	Regeneron/Sanofi's Libtayo Combined With Chemo Reduced Death By 29% In Non-small Cell Lung Cancer (RTTNews)
05.08.21	Regeneron Pharmaceuticals Q2 adjusted earnings Beat Estimates (RTTNews)
05.08.21	Regeneron Reports Second Quarter 2021 Financial and Operating Results (PR Newswire)
05.08.21	Phase 3 Trial of Libtayo® (cemiplimab-rwlc) Combined with Chemotherapy Stopped Early Due to Significant Improvement in Overall Survival in Patients with First-line Advanced Non-small Cell Lung Cancer (PR Newswire)
04.08.21	New England Journal of Medicine Publishes Positive Phase 3 Trial Results for REGEN-COV™ (casirivimab and imdevimab) to Prevent SARS-CoV-2 Infection (PR Newswire)
03.08.21	Regeneron Announces the 2021 Winners of the Regeneron Prize for Creative Innovation (PR Newswire)
30.07.21	FDA Expands Authorized Use of REGEN-COV™ (casirivimab and imdevimab) (PR Newswire)
29.07.21	Regeneron, Sanofi: Phase 3 Trial On Dupixent Met Key Endpoints At 24 Weeks (RTTNews)
29.07.21	Dupixent® (dupilumab) Significantly Improved Itch and Hives in Patients with Chronic Spontaneous Urticaria, a Step Forward in Demonstrating the Role of Type 2 Inflammation in These Patients (PR Newswire)
27.07.21	Regeneron In R&D Deal With AstraZeneca For Treatment Of Obesity (RTTNews)
27.07.21	Regeneron and AstraZeneca to Research, Develop and Commercialize New Small Molecule Medicines for Obesity (PR Newswire)
20.07.21	Japan Approves Regeneron's Antibody Cocktail To Treat Mild To Moderate COVID-19 (RTTNews)
20.07.21	Japan Becomes First Country to Approve Regeneron Antibody Cocktail (casirivimab and imdevimab) for the Treatment of Mild to Moderate COVID-19 (PR Newswire)
07.07.21	Regeneron to Report Second Quarter 2021 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2021 (PR Newswire)
01.07.21	Regeneron Genetics Center Discovers GPR75 Gene Mutations that Protect Against Obesity (PR Newswire)
28.06.21	Regeneron, Sanofi: EMA To Update Dupixent SmPC With Long-term Safety Data (RTTNews)
28.06.21	Dupixent® (dupilumab) SmPC Updated with Long-term Data Reinforcing Well-established Safety Profile in Adults with Moderate-to-severe Atopic Dermatitis (PR Newswire)
26.06.21	Intellia Announces Positive Interim Data On Transthyretin Amyloidosis Study (RTTNews)
26.06.21	Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (AT... (PR Newswire)
25.06.21	Regeneron : EC Approves Libtayo For First-line Treatment Of Advanced Non-small Cell Lung Cancer (RTTNews)
25.06.21	Libtayo® (cemiplimab) Approved by the European Commission as the First Immunotherapy Indicated for Patients with Advanced Basal Cell Carcinoma (PR Newswire)
25.06.21	Libtayo® (cemiplimab) Approved by the European Commission for First-Line Treatment of Patients with Advanced Non-small Cell Lung Cancer with ≥50% PD-L1 Expression (PR Newswire)
22.06.21	Regeneron to Participate in Guggenheim Biopharma Strategy Series (PR Newswire)
18.06.21	BioNTech Doses First Patient In BNT111 Phase 2 Cancer Vaccine Trial (RTTNews)
16.06.21	Regeneron's REGEN-COV Improves Survival In Hospitalized COVID-19 Patients (RTTNews)
16.06.21	REGEN-COV™ (casirivimab and imdevimab) Phase 3 RECOVERY Trial Meets Primary Outcome, Improving Survival in Hospitalized COVID-19 Patients Lacking an Immune Response to SARS-CoV-2 (PR Newswire)
04.06.21	FDA Updates EUA For REGEN-COV With Lower Dosage Of 1,200 Mg - Quick Facts (RTTNews)
24.05.21	Regeneron : Libtayo Gets Positive CHMP Opinion For Treatment Of Two Advanced Cancers (RTTNews)
17.05.21	Regeneron : Phase 3 Data Show Dupixent Reduces Asthma Attacks And Improves Lung Function In Children (RTTNews)
17.05.21	Regeneron Presents Detailed Results From Phase 3 Pivotal Trial For REGEN-COV - Quick Facts (RTTNews)
06.05.21	Regeneron Pharmaceuticals Q1 adjusted earnings Miss Estimates (RTTNews)
12.04.21	REGN :Phase 3 Trial Shows 81% Reduced Risk Of SARS-CoV-2 Infections With Administration Of REGEN-COV (RTTNews)
09.04.21	Regeneron: NIH Panel Recommends Use Of REGEN-COV In COVID-19 Outpatients At High Risk Of Progression (RTTNews)
23.03.21	REGN : Antibody Cocktail Reduces Hospitalization/Death By 70% In Non-hospitalized COVID-19 Patients (RTTNews)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

19.11.24		Zuversicht in New York: NASDAQ 100 mit positivem Vorzeichen
31.10.24		NASDAQ-Handel NASDAQ 100 schlussendlich in Rot
31.10.24		NASDAQ Composite-Handel aktuell: NASDAQ Composite am Donnerstagnachmittag in der Verlustzone
31.10.24		NASDAQ 100-Handel aktuell: Das macht der NASDAQ 100 aktuell
31.10.24		Zurückhaltung in New York: So performt der NASDAQ 100 aktuell
31.10.24		Angespannte Stimmung in New York: NASDAQ Composite liegt mittags im Minus
31.10.24		Zurückhaltung in New York: NASDAQ 100 zum Handelsstart im Minus
31.10.24		Donnerstagshandel in New York: NASDAQ Composite verliert zum Handelsstart